ATE247974T1 - Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen - Google Patents

Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen

Info

Publication number
ATE247974T1
ATE247974T1 AT97953156T AT97953156T ATE247974T1 AT E247974 T1 ATE247974 T1 AT E247974T1 AT 97953156 T AT97953156 T AT 97953156T AT 97953156 T AT97953156 T AT 97953156T AT E247974 T1 ATE247974 T1 AT E247974T1
Authority
AT
Austria
Prior art keywords
tnf
binding protein
treatment
combination therapy
diseases caused
Prior art date
Application number
AT97953156T
Other languages
English (en)
Inventor
Alison M Bendele
Regina M Sennello
Carl K Edwards
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE247974T1 publication Critical patent/ATE247974T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97953156T 1996-12-06 1997-12-08 Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen ATE247974T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3258796P 1996-12-06 1996-12-06
US3635597P 1997-01-23 1997-01-23
US3931597P 1997-02-07 1997-02-07
US5202397P 1997-07-09 1997-07-09
PCT/US1997/022733 WO1998024463A2 (en) 1996-12-06 1997-12-08 Combination therapy using a tnf binding protein for treating tnf-mediated diseases

Publications (1)

Publication Number Publication Date
ATE247974T1 true ATE247974T1 (de) 2003-09-15

Family

ID=27488013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97953156T ATE247974T1 (de) 1996-12-06 1997-12-08 Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen

Country Status (11)

Country Link
US (4) US6306820B1 (de)
EP (1) EP0942740B1 (de)
JP (1) JP2001513754A (de)
AT (1) ATE247974T1 (de)
AU (1) AU5696198A (de)
CA (1) CA2273850A1 (de)
DE (1) DE69724451T2 (de)
DK (1) DK0942740T3 (de)
ES (1) ES2207759T3 (de)
PT (1) PT942740E (de)
WO (1) WO1998024463A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
WO2000027421A2 (en) * 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
WO2000062790A2 (en) * 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP2003501043A (ja) * 1999-05-28 2003-01-14 ターゲティッド ジェネティクス コーポレイション 腫瘍壊死因子（ｔｎｆ）関連障害において、ｔｎｆのレベルを低下させるための方法および組成物
EP1200127B1 (de) * 1999-07-21 2008-06-25 Omeros Corporation Spüllösungen und verfahren zur schmerzhemmung, entzündungshemmung und hemmung des knorpelabbaus
EP1237575B1 (de) * 1999-12-14 2008-08-06 Genentech, Inc. Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
KR100840816B1 (ko) 2000-05-12 2008-06-23 젠자임 코포레이션 ＴＮＦ-α시그널링의 조절물질
CA2412362A1 (en) * 2000-06-20 2001-12-27 Arthur L. Heerbst Cox-2 inhibitors and the prevention of the side effects of radiation therapy
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
AU2001286701A1 (en) * 2000-08-31 2002-03-13 Genzyme Biosurgery Corporation Hyaluronan-based antiadhesion compositions, their preparation and use
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
DE10132308A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Kombinationspräparat zur Therapie von immunologischen Erkrankungen
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2004035762A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
DE60335652D1 (de) * 2002-11-21 2011-02-17 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
PT1562571E (pt) * 2002-11-21 2011-11-25 Genzyme Corp Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica
ES2304602T3 (es) 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2005110425A1 (en) * 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
WO2006059327A1 (en) 2004-12-02 2006-06-08 Can-Fite Biopharma Ltd. A biological marker for inflammation
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation
US8236306B2 (en) * 2004-12-18 2012-08-07 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US20060205682A1 (en) * 2005-02-25 2006-09-14 Roberts Richard H Antibiotic and combinations of antibiotic and symptomatic relief agent formulations
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
US8722615B2 (en) * 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
EP3085709B1 (de) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanisierte antikörper gegen menschliches rankl, pharmazeutische zusammensetzung und verwendung davon

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IN150740B (de) 1978-11-24 1982-12-04 Hoffmann La Roche
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL90339A (en) 1989-05-18 1996-10-16 Yeda Res & Dev Anti-cytotoxic protein and its purification
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
AU4660789A (en) 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ATE119942T1 (de) 1989-05-18 1995-04-15 Yeda Res & Dev Tumor-nekrosefaktor-bindungsprotein ii, seine reinigung und spezifische antikörper.
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
GB9015908D0 (en) 1990-07-19 1990-09-05 Celltech Ltd Multivalent immunoglobulin
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2100329C (en) 1991-01-18 2009-09-29 David F. Carmichael Methods for treating tumor necrosis factor mediated diseases
DE69233069T2 (de) 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
DE69213240T2 (de) 1991-07-04 1997-04-24 Immunodex K/S, Glostrup Wasserlösliche reagenzien und konjugate auf polymerbasis, die vom divinylsulfon abgeleitete reste enthalten
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
JPH07504203A (ja) * 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Also Published As

Publication number Publication date
DE69724451T2 (de) 2004-03-18
EP0942740B1 (de) 2003-08-27
US20040047863A1 (en) 2004-03-11
AU5696198A (en) 1998-06-29
JP2001513754A (ja) 2001-09-04
ES2207759T3 (es) 2004-06-01
US20040048799A1 (en) 2004-03-11
DK0942740T3 (da) 2003-12-15
US6306820B1 (en) 2001-10-23
DE69724451D1 (de) 2003-10-02
EP0942740A2 (de) 1999-09-22
HK1022440A1 (en) 2000-08-11
PT942740E (pt) 2004-01-30
CA2273850A1 (en) 1998-06-11
WO1998024463A3 (en) 1998-07-16
WO1998024463A2 (en) 1998-06-11
US20020119924A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
ATE247974T1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
AR040603A1 (es) El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
HUS1600042I1 (hu) Anti-CS1 antitestek terápiás alkalmazása
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
BG110703A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
ATE303817T1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69123984D1 (de) Verwendung von antikörpern gegen tnf oder die davon abgeleiteten fragmente und xanthinderivate in der kombinationstherapie und zusammensetzungen dazu
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
CA2468496A1 (en) Ilk inhibitors for the treatment of renal disease
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
ATE345138T1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
EP1352656A3 (de) Kombinationtherapie mit einem tnf-bindendem Protein zür behandlung von durch tnf verursachten Erkrangungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0942740

Country of ref document: EP